Swiss CDMO Siegfried has signed binding agreements with Curia Global for the acquisition of a drug substances site in Grafton, Wisconsin. The deal is expected to close by 1 July, subject to customary closing conditions. No financial details are being disclosed, other than that the acquisition is being financed from existing funds and will not change the company’s outlook for 2024 and mid-term financial targets.

Pharmaceutical CDMO AMRI has invested both in terms of scale and compound handling capabilities and new expert personnel to address orphan and rare disease products. No figure has been disclosed of the sum involved.

At its headquarters site in Albany, New York, AMRI has added additional suites for 10-15 kg batch sizes. At Grafton, Wisconsin, it has expanded its hydrogenation, filtering and drying and analytical capabilities, the latter including LC-MS and GC-MS instruments, as well as new experts. The company has also expanded at Glasgow, UK.